These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 23291299)

  • 1. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
    Kim J; Aftab BT; Tang JY; Kim D; Lee AH; Rezaee M; Kim J; Chen B; King EM; Borodovsky A; Riggins GJ; Epstein EH; Beachy PA; Rudin CM
    Cancer Cell; 2013 Jan; 23(1):23-34. PubMed ID: 23291299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hedgehog pathway inhibition and the race against tumor evolution.
    Atwood SX; Chang AL; Oro AE
    J Cell Biol; 2012 Oct; 199(2):193-7. PubMed ID: 23071148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.
    Metcalfe C; de Sauvage FJ
    Cancer Res; 2011 Aug; 71(15):5057-61. PubMed ID: 21771911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.
    Beauchamp EM; Ringer L; Bulut G; Sajwan KP; Hall MD; Lee YC; Peaceman D; Ozdemirli M; Rodriguez O; Macdonald TJ; Albanese C; Toretsky JA; Uren A
    J Clin Invest; 2011 Jan; 121(1):148-60. PubMed ID: 21183792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
    Yauch RL; Dijkgraaf GJ; Alicke B; Januario T; Ahn CP; Holcomb T; Pujara K; Stinson J; Callahan CA; Tang T; Bazan JF; Kan Z; Seshagiri S; Hann CL; Gould SE; Low JA; Rudin CM; de Sauvage FJ
    Science; 2009 Oct; 326(5952):572-4. PubMed ID: 19726788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
    Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
    Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic: a potentially useful poison for Hedgehog-driven cancers.
    Raju GP
    J Clin Invest; 2011 Jan; 121(1):14-6. PubMed ID: 21183780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with Hedgehog pathway inhibitors.
    Low JA; de Sauvage FJ
    J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of apoptotic genes and downregulation of target genes of Sonic Hedgehog signaling pathway in DAOY medulloblastoma cell line treated with arsenic trioxide.
    Ghorbanlou M; Moradi F; Shabani R; Mehdizadeh M
    J Chemother; 2024 Oct; 36(6):506-519. PubMed ID: 38130211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.
    Kim J; Tang JY; Gong R; Kim J; Lee JJ; Clemons KV; Chong CR; Chang KS; Fereshteh M; Gardner D; Reya T; Liu JO; Epstein EH; Stevens DA; Beachy PA
    Cancer Cell; 2010 Apr; 17(4):388-99. PubMed ID: 20385363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicine. Disrupting Hedgehog may reverse advanced cancer, if only temporarily.
    Kean S
    Science; 2009 Sep; 325(5945):1188. PubMed ID: 19729622
    [No Abstract]   [Full Text] [Related]  

  • 14. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector.
    Kim J; Lee JJ; Kim J; Gardner D; Beachy PA
    Proc Natl Acad Sci U S A; 2010 Jul; 107(30):13432-7. PubMed ID: 20624968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
    Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY
    Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.
    Zhao X; Ponomaryov T; Ornell KJ; Zhou P; Dabral SK; Pak E; Li W; Atwood SX; Whitson RJ; Chang AL; Li J; Oro AE; Chan JA; Kelleher JF; Segal RA
    Cancer Res; 2015 Sep; 75(17):3623-35. PubMed ID: 26130651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
    Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
    Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
    Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F
    Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.
    Ally MS; Ransohoff K; Sarin K; Atwood SX; Rezaee M; Bailey-Healy I; Kim J; Beachy PA; Chang AL; Oro A; Tang JY; Colevas AD
    JAMA Dermatol; 2016 Apr; 152(4):452-6. PubMed ID: 26765315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
    Ruiz Salas V; Alegre M; Garcés JR; Puig L
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.